{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:20:13Z","timestamp":1792200013436,"version":"4.4.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This nation-wide study describes patients with diagnosed chronic kidney disease (CKD), with and without type 2 diabetes (T2D).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Prevalence, key adverse outcomes, health care costs, and use of kidney-protective treatment, up until December 31st, 2022, were described in patients aged\u2009&gt;\u200918 years in Norway using register-based data. Only diagnosis codes were used to identify patients with CKD, with laboratory measurements of estimated-glomerular filtration rate and albuminuria unavailable. Utilisation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and renin-angiotensin system [RAS] inhibitors were evaluated in new users following the first Norwegian approval of an SGLT-2 inhibitor for CKD treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Approximately 3% (125,163 patients) of adults in Norway had diagnosed CKD (average age 70 years, 42% women, 73% without T2D). When describing patients with or without T2D, history of heart failure (22% <jats:italic>versus<\/jats:italic> 22%), atherosclerotic cardiovascular disease (ASCVD; 57% <jats:italic>versus<\/jats:italic> 51%), and atrial fibrillation (24% <jats:italic>versus<\/jats:italic> 27%) were similar. Larger proportions of those with T2D received SGLT-2 inhibitors (24% <jats:italic>versus<\/jats:italic> 4%) and\/or RAS inhibitors (63% <jats:italic>versus<\/jats:italic> 47%). Hospitalisations for CKD (28.1 <jats:italic>versus<\/jats:italic> 22.1 events per 100 patient years), heart failure (12.6 <jats:italic>versus<\/jats:italic> 9.8), myocardial infarction (3.9 <jats:italic>versus<\/jats:italic> 2.2), and stroke (3.2 <jats:italic>versus<\/jats:italic> 2.3) were more common in patients with CKD and T2D than those without T2D. However, mortality (10.8 <jats:italic>versus<\/jats:italic> 8.5) was higher in patients without T2D. CKD and heart failure costs were higher than those for ASCVD, and generally higher in patients with T2D. SGLT-2 inhibitor utilisation increased two-fold the year after its approval but was still low, used mostly at its highest target dose. Discontinuation rates were lower with SGLT-2 inhibitors than with RAS inhibitors, the latter mostly utilised at low doses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A CKD diagnosis was associated with substantial morbidity and mortality, costs, and undertreatment, both in patients with and without T2D. Use of novel kidney-protective treatment has increased, but an urgent need to improve the utilisation of kidney-protective medications remains, particularly in patients without T2D.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04171-7","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:01:53Z","timestamp":1752771713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence, outcomes, costs, and treatments of a contemporary population with chronic kidney disease in Norway: a nationwide observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Trond Geir","family":"Jenssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bodeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Anne","family":"Sveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re I.","family":"Birkeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"15","key":"4171_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"4171_CR2","doi-asserted-by":"publisher","first-page":"e074064","DOI":"10.1136\/bmjopen-2023-074064","volume":"14","author":"J Sundstr\u00f6m","year":"2024","unstructured":"Sundstr\u00f6m J, Norhammar A, Karayiannides S, Bodeg\u00e5rd J, Gustafsson S, Cars T, et al. Are there lost opportunities in chronic kidney disease? A region-wide cohort study. BMJ Open. 2024;14(4):e074064.","journal-title":"BMJ Open"},{"issue":"3","key":"4171_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.34067\/KID.0000000000000374","volume":"5","author":"N Tangri","year":"2024","unstructured":"Tangri N, Svensson MK, Bodeg\u00e5rd J, Adamsson Eryd S, Thuresson M, Gustafsson S, et al. Mortality, health care burden, and treatment of CKD: A multinational, observational study (OPTIMISE-CKD). Kidney360. 2024;5(3):352\u201362.","journal-title":"Kidney360"},{"issue":"5","key":"4171_CR4","doi-asserted-by":"publisher","first-page":"e067386","DOI":"10.1136\/bmjopen-2022-067386","volume":"13","author":"N Tangri","year":"2023","unstructured":"Tangri N, Moriyama T, Schneider MP, Virgitti JB, Nicola LD, Arnold M, et al. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13(5):e067386.","journal-title":"BMJ Open"},{"key":"4171_CR5","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the careme CKD study. Lancet Reg Health Eur. 2022;20:100438.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"4171_CR6","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"12","key":"4171_CR7","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"2","key":"4171_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY The","year":"2023","unstructured":"The EMPA-KIDNEY, Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"key":"4171_CR9","doi-asserted-by":"crossref","unstructured":"Mets\u00e4rinne K, Bodeg\u00e5rd J, Toppila I, Uusi-Rauva K, Frederiksen LE, Brinkmann S. Characteristics, treatment and disease burden among stage 3\u20134 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016\u20132022. Nephrol Dialysis Transplantation. 2024;1\u20139.","DOI":"10.1093\/ndt\/gfae242"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04171-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:13:05Z","timestamp":1757250785000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04171-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04171-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study conforms to the Declaration of Helsinki and was approved by the Regional Ethics Committee, Helse S\u00f8r-\u00d8st (approval numbers 2015\/1337\/REK S\u00f8r-\u00d8st A and 11744), and the Norwegian Data Inspectorate (Datatilsynet). The Regional Ethics Committee, Helse S\u00f8r-\u00d8st, waived the need for informed consent from the patients included in the study, given that the study only used data that had already been collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.I.B. has received grants to his institution from AstraZeneca for this study and for lectures and consulting from Novo Nordisk, Sanofi, Lilly, Boehringer Ingelheim and Merck Sharp & Dohme. K.A.S. has received speaking honoraria from AstraZeneca, Novo Nordisk, Sanofi, Eli Lilly and Boehringer Ingelheim. T.G.J. has received lecture fees from NovoNordisk, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Bayer Pharmaceuticals. M.T. holds a full-time position by an independent statistical consultant company, Statisticon AB, Uppsala, Sweden, of which AstraZeneca Nordic is a client. J.B. holds a full-time position at AstraZeneca as an epidemiologist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}